Charcot-Marie-Tooth Disease Clinical Trials

Find Charcot-Marie-Tooth Disease Clinical Trials Near You

Clinical Trial Evaluating the Impact of an Intensive Rehabilitation Program Combined With Tendon Vibratory Stimulation on Functional Balance in Individuals With Charcot-Marie-Tooth Disease Type 1A

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Charcot-Marie-Tooth (CMT) disease is caused by a genetic abnormality involving the PMP22 gene, resulting in demyelination of the peripheral nerves. Demyelination leads to sensorimotor impairment and causes progressive muscle weakness and tendon contractures, initially affecting the lower limbs. Consequently, individuals with CMT experience balance impairments and gait disturbances, including ankle instability, foot drop, and postural instability, which lead to frequent falls and reduced quality of life. Currently, there is no disease-modifying treatment for CMT. Several rehabilitation approaches have been proposed, including endurance training and muscle strengthening programs, to improve independence in activities of daily living. However, rehabilitation practices for individuals with CMT remain poorly standardized, and there is still a lack of clearly defined rehabilitation protocols, despite broad agreement among healthcare professionals regarding their potential benefits. More recently, noninvasive focal tendon vibration has been investigated in several neurological disorders to improve sensory function, balance, and motor performance. Previous studies suggest that mechanical vibratory stimulation applied to the quadriceps tendon may induce sustained improvements in postural control and lower-limb muscle strength. The present study aims to evaluate a rehabilitation program combined with tendon vibratory stimulation. The objective is to compare the effectiveness of a short-term (2-week), intensive multidisciplinary rehabilitation program focused on balance with different types of focal tendon vibration, in order to better address balance impairments and their associated complications in individuals with Charcot-Marie-Tooth disease.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Individuals with genetically confirmed Charcot-Marie-Tooth disease type 1A (CMT1A), characterized by PMP22 gene duplication on chromosome 17 (17p11.2).

• Age between 18 and 65 years.

• Overall Neuropathy Limitations Scale (ONLS) score between 2 and 3/7 for the lower limbs.

• Affiliation with a social security/health insurance system.

• Written informed consent voluntarily provided after receiving information regarding the study objectives, procedures, and potential risks.

Locations
Other Locations
France
IUR Valmante Sud
RECRUITING
Marseille
Contact Information
Primary
Laurent Bensoussan, MD
laurent.bensoussan@ugecam.assurance-maladie.fr
+33 4 91 74 42 00
Backup
Clotilde Pheulpin, MD
Time Frame
Start Date: 2025-04-28
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 30
Treatments
Experimental: With mechanical vibratory stimulation
Sham_comparator: Without mechanical vibratory stimulation
Sponsors
Leads: UGECAM PACA et Corse

This content was sourced from clinicaltrials.gov